Lilly Partners with Ypsomed for AID System; Tidepool Lays Off 40% of Staff
Two diabetes-related news items have been observed: Lilly and Ypsomed announced a partnership for the commercialization of Ypsomed’s AID system and Tidepool announced layoffs accounting for 40% of their staff. Below, FENIX provides highlights and insights for the respective news items, including thoughts on if the Lilly/Ypsomed partnership may be an admission from Lilly that its AID development is behind expectations and how the material experience of Mike Mason may have contributed to this deal getting done.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.